Please use this identifier to cite or link to this item:
|Type:||Artigo de periódico|
|Title:||Raloxifene Action On Bone And Efficacy On Reduction Of Fracture Risk [ação Do Raloxifeno No Tecido ósseo E Sua Eficácia Na Redução Do Risco De Fraturas]|
|Author:||Marques Neto J.F.|
Jeha Kayath M.
|Abstract:||We de scribe raloxifene action in the bone and compare raloxifene data with other anti-resorption drugs studies. The main objective of any treatment of postmenopausal osteoporosis is to prevent bone fractures. There are many effective choices of treatment, which are able to reduce bone fracture risk in women with postmenopausal osteoporosis. Raloxifene, a selective estrogen receptor modulator, acts by binding to the estrogen receptor. At the bone, raloxifene, promotes effects as estrogen does, acting as an estrogen agonist. Consequently, raloxifene reduces bone resorption, as seen by the reduction of resorption bone markers, increases bone mineral density at different sites and also reduces the risk of vertebral fractures in postmenopausal women. The MORE study has showed that raloxifene reduces the incidence of vertebral clinical fractures in postmenopausal women with osteoporosis during the first year of treatment, and reduces the incidence of vertebral fractures after 3 years of treatment in the same group of patients. Recently, from MORE study, 4 years of treatment with raloxifene results were published confirming that raloxifene continuously prevents vertebral fractures in a sustainable fashion. Raloxifene reduces the incidence of new breast cancer and improves lipid features in postmenopausal women. We conclude that there are data in literature to support raloxifene as an efficacious treatment of postmenopausal osteoporosis women.|
|Appears in Collections:||Unicamp - Artigos e Outros Documentos|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.